These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33673305)

  • 41. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro.
    Weissenstein U; Kunz M; Oufir M; Wang JT; Hamburger M; Urech K; Regueiro U; Baumgartner S
    BMC Complement Altern Med; 2019 Jan; 19(1):23. PubMed ID: 30658716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
    Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
    J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
    Hwang GS; Bhat R; Crutchley RD; Trivedi MV
    Pharmacogenomics J; 2018 Apr; 18(2):201-208. PubMed ID: 28762370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
    Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
    Chao TC; Pan WC; Tsai YF; Chou YC; Liu YR; Wang SF; Chen YJ; Souček P; Ueng YF
    Toxicol Appl Pharmacol; 2019 Sep; 378():114619. PubMed ID: 31195002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
    Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
    Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
    [TBL] [Abstract][Full Text] [Related]  

  • 53. National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
    Lin G; Zhang K; Yi L; Han Y; Xie J; Li J
    PLoS One; 2016; 11(9):e0162361. PubMed ID: 27603206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
    Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC;
    Breast Cancer Res Treat; 2019 Feb; 173(3):521-532. PubMed ID: 30411242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
    Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
    Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenomics of endocrine therapy in breast cancer.
    Weinshilboum R
    Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.
    Cronin-Fenton DP; Damkier P
    Adv Pharmacol; 2018; 83():65-91. PubMed ID: 29801584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
    Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
    Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.